The hypothalamus-pituitary-thyroid axis in critical illness

Netherlands Journal of Medicine

Volumn 67, Issue 10, 2009, Pages 332-340

  Mebis, L ^a   Van Den Berghe, G ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Critical illness; Deiodinase; Hypothalamic TRH; Low T3 syndrome; MCT8; TSH

Indexed keywords

LIOTHYRONINE; MONOCARBOXYLATE TRANSPORTER; MONOCARBOXYLATE TRANSPORTER 8; PROTIRELIN; THYROTROPIN; THYROXINE;

CELL MEMBRANE; CRITICAL ILLNESS; GENE ACTIVATION; HORMONE TRANSPORT; HUMAN; HYPOPHYSIS; HYPOTHALAMUS; NONHUMAN; REVIEW; THYROID GLAND;

ANIMALS; CRITICAL ILLNESS; CYTOKINES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IODIDE PEROXIDASE; THYROID GLAND; THYROID HORMONES; THYROTROPIN; THYROTROPIN-RELEASING HORMONE; THYROXINE; TRIIODOTHYRONINE;

EID: 70549089773     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Van den Berghe G, de Zegher F, Bouillon R. Acute and Prolonged Critical Illness as Different Neuroendocrine Paradigms. J Clin Endocrinol Metab. 1998;83(6):1827-1834 (Pubitemid 28496301)
2. Kinney JM, Duke JH Jr., Long CL, Gump FE. Tissue fuel and weight loss after injury. J Clin Pathol Suppl (R Coll Pathol). 1970;4:65-72.
3. Cahill GF, Jr. Starvation in man. N Engl J Med. 1970;282(12):668-675
4. Utiger RD. Decreased extrathyroidal triiodothyronine production in non-thyroidal illness: benefit or harm? Am J Med. 1980;69(6):807-810
5. Streat SJ, Beddoe AH, Hill GL. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. J Trauma. 1987;27(3):262-266
6. Gamrin L, Essen P, Forsberg AM, Hultman E, Wernerman J. A descriptive study of skeletal muscle metabolism in critically ill patients: free amino acids, energy-rich phosphates, protein, nucleic acids, fat, water, and electrolytes. Crit Care Med. 1996;24(4):575-583 (Pubitemid 26133789)
7. Van den Berghe G, de Zegher F, Veldhuis JD, et al. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab. 1997 1;82(2):590-599
8. Van den Berghe G, de Zegher F, Veldhuis JD, et al. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf). 1997;47(5):599-662
9. Van den Berghe G, de Zegher F, Baxter RC, et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab. 1988;83(2):309-319
10. Chopra IJ, Chopra U, Smith SR, Reza M, Solomon DH. Reciprocal changes in serum concentrations of 3,3′,5-triiodothyronine (T3) in systemic illnesses. J Clin Endocrinol Metab. 1975;41(6):1043-1049
11. Michalaki M, Vagenakis AG, Makri M, Kalfarentzos F, Kyriazopoulou V. Dissociation of the early decline in serum T(3) concentration and serum IL-6 rise and TNFalpha in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab. 2001;86(9):4198-4205
12. Gardner DF, Kaplan MM, Stanley CA, Utiger RD. Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med. 1979;300(11):579-584
13. Acker CG, Singh AR, Flick RP, Bernardini J, Greenberg A, Johnson JP. A trial of thyroxine in acute renal failure. Kidney Int. 2000;57(1):293-298 (Pubitemid 30227777)
14. Bettendorf M, Schmidt KG, Grulich-Henn J, Ulmer HE, Heinrich UE. Tri-iodothyronine treatment in children after cardiac surgery: a double-blind, randomised, placebo-controlled study. Lancet. 2000;356(9229):529-534 (Pubitemid 30611856)
15. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986;63(1):1-8.
16. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995;333(23):1522-1527
17. Marks SD, Haines C, Rebeyka IM, Couch RM. Hypothalamic-pituitary-thyroid axis changes in children after cardiac surgery. J Clin Endocrinol Metab. 2009;94(8):2781-2786
18. Van Wassenaer AG, Kok JH, de Vijlder JJ, et al. Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation. N Engl J Med. 1997;336(1):21-26
19. Vanhole C, Aerssens P, Naulaers G, et al. L-thyroxine treatment of preterm newborns: clinical and endocrine effects. Pediatr Res. 1997;42(1):87-92.
20. Fliers E, Alkemade A, Wiersinga WM. The hypothalamic-pituitary-thyroid axis in critical illness. Best Pract Res Clin Endocrinol Metab. 2001;15(4):453-464 (Pubitemid 34884220)
21. Davis PJ, Davis FB. Nongenomic actions of thyroid hormone. Thyroid. 1996;6(5):497-504.
22. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001;81(3):1097-1142 (Pubitemid 32606667)
23. Schwartz HL, Trence D, Oppenheimer JH, Jiang NS, Jump DB. Distribution and metabolism of L- and D-triiodothyronine (T3) in the rat: preferential accumulation of L-T3 by hepatic and cardiac nuclei as a probable explanation of the differential biological potency of T3 enantiomers. Endocrinology. 1983;113(4):1236-1243
24. Samuels HH, Stanley F, Casanova J. Relationship of receptor affinity to the modulation of thyroid hormone nuclear receptor levels and growth hormone synthesis by L-triiodothyronine and iodothyronine analogues in cultured GH1 cells. J Clin Invest. 1979;63(6):1229-1240 (Pubitemid 9193219)
25. Hennemann G, Docter R, Friesema EC, de Jong M, Krenning EP, Visser TJ. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev. 2001;22(4):451-476 (Pubitemid 32762323)
26. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, Cellular and Molecular Biology, and Physiological Roles of the Iodothyronine Selenodeiodinases. Endocr Rev. 2002;23(1):38-891
27. Boelen A, Kwakkel J, Thijssen-Timmer DC, Alkemade A, Fliers E, Wiersinga WM. Simultaneous changes in central and peripheral components of the hypothalamus-pituitary-thyroid axis in lipopolysaccharide-induced acute illness in mice. J Endocrinol. 2004;182(2):315-323 (Pubitemid 39199015)
28. Debaveye Y, Ellger B, Mebis L, et al. Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2. Endocrinology. 2005;146(12):5604-5611 (Pubitemid 41653077)
29. Mebis L, Langouche L, Visser TJ, van den Berghe G. The type II iodothyronine deiodinase is up-regulated in skeletal muscle during prolonged critical illness. J Clin Endocrinol Metab. 2007;92(8):3330-3333 (Pubitemid 47236410)
30. Mebis L, Paletta D, Debaveye Y, et al. Expression of thyroid hormone transporters during critical illness. Eur J Endocrinol. 2009;161(2):243-250
31. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab. 2003;88(7):3202-3211 (Pubitemid 36877495)
32. Thijssen-Timmer DC, Peeters RP, Wouters P, et al. Thyroid hormone receptor isoform expression in livers of critically ill patients. Thyroid 2007;17(2):105-112 (Pubitemid 46365564)
33. Luiza Maia A, Kim BW, Huang SA, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest. 2005;115(9):2524-2533
34. Bianco AC, Larsen PR. Cellular and structural biology of the deiodinases. Thyroid. 2005;15(8):777-786
35. Leonard JL, Koehrle J. Intracellular pathways of iodothyronine metabolism. Philadelphia: Lippincott Williams & Wilkins, 2000.
36. Zimmerman D. Fetal and neonatal hyperthyroidism. Thyroid. 1999;9(7):727-733
37. Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med. 2000;343(3):185-189
38. Chopra IJ, Wu SY, Teco GN, Santini F. A radioimmunoassay for measurement of 3,5,3′-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and neonatal life. J Clin Endocrinol Metab. 1992;75(1):189-194
39. Eelkman Rooda SJ, Kaptein E, Visser TJ. Serum triiodothyronine sulfate in man measured by radioimmunoassay. J Clin Endocrinol Metab. 1989;69(3):552-556 (Pubitemid 19221226)
40. Peeters RP, Kester MH, Wouters PJ, et al. Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type I deiodinase activity. J Clin Endocrinol Metab. 2005;90(12):6460-6465
41. den Brinker M, Joosten KF, Visser TJ, et al. Euthyroid sick syndrome in meningococcal sepsis: the impact of peripheral thyroid hormone metabolism and binding proteins. J Clin Endocrinol Metab. 2005;90(10):5613-5620
42. Crantz FR, Silva JE, Larsen PR. An analysis of the sources and quantity of 3,5,3′-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum. Endocrinology. 1982;110(2):367-375
43. Larsen PR, Silva JE, Kaplan MM. Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocr Rev. 1981;2(1):87-102.
44. Oppenheimer JH. Role of plasma proteins in the binding, distribution and metabolism of the thyroid hormones. N Engl J Med. 1968;278(21):1153-1162
45. Farer LS, Robbins J, Blumberg BS, Rall JE. Thyroxine-serum protein complexes in various animals. Endocrinology. 1962;70:686-696
46. Refetoff S, Robin NI, Fang VS. Parameters of thyroid function in serum of 16 selected vertebrate species: a study of PBI, serum T4, free T4, and the pattern of T4 and T3 binding to serum proteins. Endocrinology. 1970;86(4)793-805.
47. Afandi B, Vera R, Schussler GC, Yap MG. Concordant decreases of thyroxine and thyroxine binding protein concentrations during sepsis. Metabolism. 2000;49(6):753-754 (Pubitemid 30354583)
48. Afandi B, Schussler GC, Arafeh AH, Boutros A, Yap MG, Finkelstein A. Selective consumption of thyroxine-binding globulin during cardiac bypass surgery. Metabolism. 2000;49(2):270-274 (Pubitemid 30090896)
49. Chopra IJ, Huang TS, Beredo A, Solomon DH, Chua Teco GN, Mead JF. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3′-triiodothyronine in sera of patients with nonthyroidal illnesses. J Clin Endocrinol Metab. 1985;60(4):666-672
50. Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev. 1996;17(1):45-63. (Pubitemid 26061367)
51. Lim CF, Docter R, Visser TJ, Krenning EP, et al. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and nonesterified fatty acids. J Clin Endocrinol Metabol. 1993;76(5):1165-1172 (Pubitemid 23155430)
52. Same DH, Refetoff S. Measurement of thyroxine uptake from serum by cultured human hepatocytes as an index of thyroid status: reduced thyroxine uptake from serum of patients with nonthyroidal illness. J Clin Endocrinol Metab. 1985;61(6):1046-1052 (Pubitemid 16186700)
53. Vos RA, de Jong M, Bernard BF, Docter R, Krenning EP, Hennemann G. Impaired thyroxine and 3,5,3′-triiodothyronine handling by rat hepatocytes in the presence of serum of patients with nonthyroidal illness. J Clin Endocrinol Metab. 1995;80(8):2364-2370
54. Lim CF, Docter R, Krenning EP, et al. Transport of thyroxine into cultured hepatocytes: effects of mild non-thyroidal illness and calorie restriction in obese subjects. Clin Endocrinol (Oxf). 1994;40(1)79-85. (Pubitemid 24193131)
55. Hennemann G, Krenning EP, Polhuys M, et al. Carrier-mediated transport of thyroid hormone into rat hepatocytes is rate-limiting in total cellular uptake and metabolism. Endocrinology. 1986;119(4):1870-1872 (Pubitemid 17170565)
56. Hennemann G, Everts ME, de Jong M, Lim CF, Krenning EP, Docter R. The significance of plasma membrane transport in the bioavailability of thyroid hormone. Clin Endocrinol (Oxf). 1998;48(1):1-8. (Pubitemid 28122426)
57. Bodoky G, Yang ZJ, Meguid MM, Laviano A, Szeverenyi N. Effects of fasting, intermittent feeding, or continuous parenteral nutrition on rat liver and brain energy metabolism as assessed by 31P-NMR. Physiol Behav. 1995;58(3):521-527
58. Krenning EP, Docter R, Bernard B, Visser T, Hennemann G. Decreased transport of thyroxine (T4), 3,3′,5-triiodothyronine (T3) and 3,3′,5′-triiodothyronine (rT3) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs. FEBS Lett. 1982;140(2):229-233
59. De Jong M, Docter R, Bernard BF, et al. T4 uptake into the perfused rat liver and liver T4 uptake in humans are inhibited by fructose. Am J Physiol. 1994;266(5 Pt 1):E768-75.
60. Surks MI, Hupart KH, Pan C, Shapiro LE. Normal free thyroxine in critical nonthyroidal illnesses measured by ultrafiltration of undiluted serum and equilibrium dialysis. J Clin Endocrinol Metab.1988;67(5):1031-1039 (Pubitemid 18277226)
61. Melmed S, Geola FL, Reed AW, Pekary AE, Park J, Hershman JM. A comparison of methods for assessing thyroid function in nonthyroidal illness. J Clin Endocrinol Metab. 1982;54(2):300-306
62. Kaptein EM, MacIntyre SS, Weiner JM, Spencer CA, Nicoloff JT. Free thyroxine estimates in nonthyroidal illness: comparison of eight methods. J Clin Endocrinol Metab. 1981;52(6):1073-1077 (Pubitemid 13237506)
63. Chopra IJ, Solomon DH, Hepner GW, Morgenstein AA. Misleadingly low free thyroxine index and usefulness of reverse triiodothyronine measurement in nonthyroidal illnesses. Ann Intern Med. 1979;90(6):905-912
64. Peeters RP, van der Geyten S, Wouters PJ, et al. Tissue Thyroid Hormone Levels in Critical Illness. J Clin Endocrinol Metab. 2005;90(12):6498-6507 (Pubitemid 41759305)
65. Arem R, Wiener GJ, Kaplan SG, Kim HS, Reichlin S, Kaplan MM. Reduced tissue thyroid hormone levels in fatal illness. Metabolism. 1993;42(9):1102-1108 (Pubitemid 23292684)
66. Sap J, Munoz A, Damm K, et al. The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature. 1986;324(6098):635-640 (Pubitemid 17206350)
67. Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM. The c-erb-A gene encodes a thyroid hormone receptor. Nature. 1986;324(6098):641-646 (Pubitemid 17206351)
68. Brent GA, Dunn MK, Harney JW, Gulick T, Larsen PR, Moore DD. Thyroid hormone aporeceptor represses T3-inducible promoters and blocks activity of the retinoic acid receptor. New Biol. 1989;1(3):329-336
69. Koenig RJ, Lazar MA, Hodin RA, et al. Inhibition of thyroid hormone action by a non-hormone binding c-erbA protein generated by alternative mRNA splicing. Nature. 1989;337(6208):659-661
70. Van den Berghe G. Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol 2002;23(4):370-391 (Pubitemid 35346212)
71. Bacci V, Schussler GC, Kaplan TB. The relationship between serum triiodothyronine and thyrotropin during systemic illness. J Clin Endocrinol Metab. 1982;54(6):1229-1235 (Pubitemid 13238706)
72. Hamblin PS, Dyer SA, Mohr VS, et al. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. J Clin Endocrinol Metab. 1986;62(4):717-722
73. Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab. 1997;82(12):4032-4036 (Pubitemid 27525507)
74. Boelen A, Platvoet-ter Schiphorst MC, Bakker O, Wiersinga WM. The role of cytokines in the lipopolysaccharide-induced sick euthyroid syndrome in mice. J Endocrinol. 1995;146(3):475-483
75. Boelen A, Schiphorst MC, Wiersinga WM. Relationship between serum 3,5,3′-triiodothyronine and serum interleukin-8, interleukin-10 or interferon gamma in patients with nonthyroidal illness. J Endocrinol Invest. 1996;19(7):480-483
76. Boelen A, Kwakkel J, Platvoet-Ter Schiphorst M, et al. Interleukin-18, a proinflammatory cytokine, contributes to the pathogenesis of non-thyroidal illness mainly via the central part of the hypothalamus-pituitary-thyroid axis. Eur J Endocrinol. 2004;151(4):497-502. (Pubitemid 39430269)
77. Van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab. 1990;71(6):1567-1572
78. Boelen A, Platvoet-ter Schiphorst MC, Wiersinga WM. Association between serum interleukin-6 and serum 3,5,3′-triiodothyronine in nonthyroidal illness. J Clin Endocrinol Metab. 1993;77(6):1695-1699
79. Van der Poll T, van Zee KJ, Endert E, et al. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab. 1995;80(4):1341-1346
80. Boelen A, Platvoet-ter Schiphorst MC, Wiersinga WM. Immunoneutralization of interleukin-1, tumor necrosis factor, interleukin-6 or interferon does not prevent the LPS-induced sick euthyroid syndrome in mice. J Endocrinol. 1997;153(1):115-122 (Pubitemid 27146264)
81. Mebis L, Debaveye Y, Ellger B, et al. Changes in the central component of the hypothalamus-pituitary-thyroid axis in a rabbit model of prolonged critical illness. Crit Care. 2009;13(5):R147.
82. Fekete C, Gereben B, Doleschall M, et al. Lipopolysaccharide induces type 2 iodothyronine deiodinase in the mediobasal hypothalamus: implications for the nonthyroidal illness syndrome. Endocrinology. 2004;145(4):1649-1655 (Pubitemid 38402371)
83. Fekete C, Sarkar S, Christoffolete MA, Emerson CH, Bianco AC, Lechan RM. Bacterial lipopolysaccharide (LPS)-induced type 2 iodothyronine deiodinase (D2) activation in the mediobasal hypothalamus (MBH) is inde pendent of the LPS-induced fall in serum thyroid hormone levels. Brain Res. 2005;1056(1):97-99
84. Fekete C, Singru PS, Sarkar S, Rand WM, Lechan RM. Ascending brainstem pathways are not involved in lipopolysaccharide-induced suppression of thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus. Endocrinology. 2005;146(3):1357-1363 (Pubitemid 40289323)
85. Baur A, Bauer K, Jarry H, Kohrle J. Effects of proinflammatory cytokines on anterior pituitary 5′-deiodinase type I and type II. J Endocrinol. 2000;167(3):505-515 (Pubitemid 32047558)
86. Zeold A, Doleschall M, Haffner MC, et al. Characterization of the nuclear factor-kappa B responsiveness of the human dio2 gene. Endocrinology. 2006;147(9):4419-4429 (Pubitemid 44268393)
87. Boelen A, Kwakkel J, Wiersinga WM, Fliers E. Chronic local inflammation in mice results in decreased TRH and type 3 deiodinase mRNA expression in the hypothalamic paraventricular nucleus independently of diminished food intake. J Endocrinol. 2006;191(3):707-714 (Pubitemid 46210295)
88. Dumitrescu AM, Liao XH, Weiss RE, Millen K, Refetoff S. Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (mct) 8-deficient mice. Endocrinology. 2006;147(9):4036-4043 (Pubitemid 44268357)
89. Trajkovic M, Visser TJ, Mittag J, et al. Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. J Clin Invest. 2007;117(3):627-635 (Pubitemid 46348521)
90. Lechan RM, Fekete C. Role of melanocortin signaling in the regulation of the hypothalamic-pituitary-thyroid (HPT) axis. Peptides. 2006;27(2):310-325 (Pubitemid 43168170)
91. Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature. 1996;382(6588):250-252 (Pubitemid 26251358)
92. Legradi G, Emerson CH, Ahima RS, Flier JS, Lechan RM. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology. 1997;138(6):2569-2576 (Pubitemid 27215264)
93. Sergeyev V, Broberger C, Hokfelt T. Effect of LPS administration on the expression of POMC, NPY, galanin, CART and MCH mRNAs in the rat hypothalamus. Brain Res Mol Brain Res. 2001;90(2):93-100. (Pubitemid 32537630)
94. Becker RA, Vaughan GM, Ziegler MG, Seraile LG, Goldfarb IW, Mansour EH, et al. Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med. 1982;10(12):870-875
95. Debaveye Y, Van den Berghe G. Is there still a place for dopamine in the modern intensive care unit? Anesth Analg. 2004;98(2):461-468
96. Van den Berghe G, de Zegher F, Vlasselaers D, et al. Thyrotropin- releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations. Crit Care Med. 1996;24(4):590-595 (Pubitemid 26133791)
97. Van den Berghe G, de Zegher F, Bowers CY, et al. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness. Clin Endocrinol. 1996;45(3):341-351